BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Promedico Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Promedico Ltd.'s drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04442022-2266@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Selinexor\, phase 2/3.\nStudy: A Study of Rituximab-Gemcitabine
 -Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With
  Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04442022
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2266@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Selinexor\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor and
  Backbone Treatments of Multiple Myeloma Patients\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 linexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02343042
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-2266@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Selinexor: Phase 2 readout est. (NCT05980806)
DESCRIPTION:Selinexor\, phase 2\, Myelofibrosis.\nStudy: A Study of Selinex
 or Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Mod
 erate Thrombocytopenia\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05980806
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-2266@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selinexor: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: A Study of Seli
 nexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple M
 yeloma (MM)\, Seli and Bortezomib + LDD in Triple-class Refractory MM.\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
